Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy and safety of pazopanib as adjuvant therapy for subjects with localized or locally advanced RCC following nephrectomy

Next Previous
Trial Profile

A randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy and safety of pazopanib as adjuvant therapy for subjects with localized or locally advanced RCC following nephrectomy

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 21 Jun 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pazopanib (Primary)
  • Indications Renal cell carcinoma
  • Focus Registrational; Therapeutic Use
  • Acronyms PROTECT
  • Sponsors GlaxoSmithKline; GSK; Novartis; Novartis Pharmaceuticals

Most Recent Events

  • 06 May 2024 Genomic data has been derived and presented at the 119th Annual Meeting of the American Urological Association
  • 04 Jul 2022 Results of meta analysis from KEYNOTE-564, S-TRAC, ASSURE, PROTECT, ATLAS, and SORCE, presented at the 37th Congress of the European Association of Urology
  • 16 May 2022 Systemic and meta-analysis from six trials (KEYNOTE-564, S-TRAC, ASSURE, PROTECT, ATLAS, and SORCE) presented at the 117th Annual Meeting of the American Urological Association

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top